| Literature DB >> 32904369 |
Enrico Ammirati1,2, Francesco Moroni1, Marco Magnoni1, Maria A Rocca3, Roberta Messina3, Nicoletta Anzalone4, Costantino De Filippis4, Isabella Scotti5, Francesca Besana6, Pietro Spagnolo6,7, Ornella E Rimoldi8, Roberto Chiesa1, Andrea Falini4, Massimo Filippi3, Paolo G Camici1.
Abstract
BACKGROUND AND AIMS: Extent of subclinical atherosclerosis has been associated with brain parenchymal loss in community-dwelling aged subjects. Identification of patient-related and plaque-related markers could identify subjects at higher risk of brain atrophy, independent of cerebrovascular accidents. Aim of the study was to investigate the relation between extent and characteristics of carotid plaques and brain atrophy in asymptomatic patients with no indication for revascularization. METHODS ANDEntities:
Keywords: Brain atrophy; Brain magnetic resonance imaging; Brain volumes; CC-IMT, common carotid intima media thickness; CEUS, contrast enhanced ultrasound; CV, cardiovascular; Cardiovascular risk factors; Carotid atherosclerosis; GFR, glomerular filtration rate; GM, gray matter; TBV, total brain volume; TPA, total plaque area; Vulnerable plaque; WM, white matter
Year: 2020 PMID: 32904369 PMCID: PMC7452655 DOI: 10.1016/j.ijcha.2020.100619
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Exclusion criteria for participation in the study.
| Exclusion criteria for the IMPLAC study |
|---|
| Age < 18 or >85 years |
| Contraindications to CTA (eGFR < 30 mL/min; history of allergic reaction to iodinated contrast media) |
| Pregnancy or child-bearing potential |
| Specific contraindication to MRI: Claustrophobia Sickle cell anemia Systemic mastocytosis Implanted cardiac devices (PM, ICD) Vascular clips Vertebral distractors Infusion pumps Neurostimulators Liquor derivations Any device which could be dispositioned in the presence of a strong magnetic field |
| Dementia |
| Life expectancy less than study follow up (18 months) |
| History of drug abuse, alcohol abuse or any psychiatric or social condition which may contraindicate the participation to a clinical study |
| Vertebral artery occlusion |
| Previous revascularization of the carotid artery |
| Current anti-coagulation |
| Atrial fibrillation not necessitating anticoagulation |
| Known PFO necessitating anti-platelet treatment |
| Previous cerebrovascular accidents |
| Previous infections to the CNS |
| Previous surgery to the CNS |
| History of anoxic damage to the CNS |
| Previous cardiac surgery or positioning of intracardiac devices (excluded coronary stents) |
| History of autoimmune vasculitis |
Population characteristics. *n = 57, seven patients did not have recent blood tests.
| Patients (n = 64) | |
|---|---|
| Demographic Characteristics | |
| Age, years | 69 ± 8 |
| Female, n (%) | 28 (45) |
| Cardiovascular Risk Factors | |
| Family history of coronary artery disease, n(%) | 22 (34) |
| Family history of stroke, n(%) | 8 (13) |
| Systemic arterial hypertension, n(%) | 49 (77) |
| Resistant hypertension, n(%) | 10 (16) |
| Hypercholesterolemia, n(%) | 46 (72) |
| Type 2 diabetes mellitus, n(%) | 16 (25) |
| Current smoker, n(%) | 28 (44) |
| Previous smoker, n(%) | 11 (27) |
| Body mass index (kg/cm2) | 25 ± 4 |
| Framingham risk score (%) | 12 (6–19) |
| High cardiovascular risk n(%) | 35 (55) |
| Previous acute coronary syndrome, n (%) | 12 (19) |
| Laboratory Parameters* | |
| White blood cells, 109/L | 7.2 (6–9) |
| Haemoglobin, g/dL | 14 (13–15) |
| AST, UI/L | 20 (16–25) |
| ALT, UI/L | 20 (15–27) |
| Platelets, 109/L | 205 (160–253) |
| Total cholesterol, mg/dL | 174 (155–196) |
| LDL cholesterol, mg/dL | 104 (85–122) |
| HDL cholesterol, mg/dL | 43 (38–50) |
| Triglyceridemia, mg/dL | 128 (95–161) |
| Glycemia, mg/dL | 99 (88–128) |
| Creatinine, mg/dL | 0.85 (0.73–1.04) |
| eGFR, mL/min | 72 (58–96) |
| Medical Therapy | |
| ACE inhibitors, n (%) | 20 (31) |
| Angiotensin Receptor Blockers, n (%) | 19 (30) |
| β-blockers, n(%) | 26 (41) |
| Calcium antagonists, n(%) | 16 (25) |
| Diuretics, n (%) | 13 (20) |
| Others vasodilators, n(%) | 4 (6) |
| Number of anti-hypertensive agents | 2 (1–5) |
| Statins, n(%) | 39 (61) |
| Antiplatelet agent - n(%) | 39 (61) |
| Oral diabetes medications, n(%) | 13 (20) |
| Insulin therapy, n (%) | 2 (3) |
Fig. 1Brain volumes of two representative subjects. Panels A-C show respectively a transverse, sagittal and coronal reconstruction of 3D T1-weighted brain scan from the same patient. The subject had a total normalized brain volume of 1451 mL, with 759 mL of grey matter and 692 mL of white matter. Panels D-F show an ultrasound, contrast enhanced ultrasound (CEUS) and computed tomography angiography (CTA) of the right carotid bulb of the same patient. The plaque (white arrows) appears to be lipid rich, as showed by hypoechogenic images in B-mode ultrasound. The plaque also had a lower attenuation in CTA images (274HU). Panels G-I show brain images from a different patient reconstructed at comparable levels. The second subject had more pronounced reduction of cerebral volumes, with a total brain volume of 1341 mL, a grey matter volume of 700 mL and white matte volume of 641 mL. Panels L-N show ultrasound, CEUS and CTA images of the right carotid bifurcation of the second subject. This time the plaque (white arrows) appears markedly fibrocalcific, as demonstrated by posterior acoustic shadows (white arrowheads) in ultrasound images. CTA demonstrates a high attenuation, with a plaque density of 1368HU. In CTA images, the blue line delimitated the contour of the carotid artery, while the blue line showed the lumen of the artery. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2Association between cardiovascular risk factors and cerebral volumes. Panels A-C show the significant associations between brain volumes and age; panels D and E the correlation between brain volumes and renal function; panel F the association between grey matter volume and overall cardiovascular risk. WM = white matter; GM = grey matter; eGFR = estimated glomerular filtration rate; FRS = 10-year Framingham risk score.
Fig. 3Associations between carotid atherosclerosis features and cerebral volumes. Panels A and B show the association between atherosclerotic burden estimated as number of carotid segments involved by the atherosclerotic process and total brain volume and white matter volume. Panels C and D show the significant inverse correlation between plaque density and total and grey matter volumes; the last two panels show the significant association between plaque composition evaluated with ultrasound and total and grey matter volumes. WM = white matter; GM = grey matter; HU = Hounsfield’s unit.
Multivariate regression analysis. eGFR = estimated glomerular filtration rate; CC-IMT = common carotid intima-media thickness; TPA = total plaque area; N° segments = number of segments involved by atherosclerosis as identified by ultrasound; BMI = body mass index; FRS = 10-years Framingham risk score; HTN = hypertension.
| Total brain volume | |||
|---|---|---|---|
| Variable | β | CI (95%) | p |
| (Intercept) | 1745.6 | 1556.3; 1934.8 | <0.0001 |
| Age | −3.2 | −5.3; −0.9 | 0.003 |
| eGFR | −0.04 | −0.7; 0.6 | 0.90 |
| CC-IMT | −63.8 | −154.4; 26.8 | 0.16 |
| TPA | 2.2 | −35.3; 3.9 | 0.90 |
| N° of segments | −5.4 | −15.8; 4.9 | 0.29 |
| Plaque density | −0.03 | −0.06; −0.003 | 0.03 |
| Plaque composition | −24.7 | −53,9; 4.5 | 0.09 |
| GM volume | |||
| Variable | β | CI (95%) | p |
| (Intercept) | 895.6 | 794.1; 997.1 | <0.0001 |
| Age | −0.8 | −2.1; 0.5 | 0.22 |
| BMI | −1.2 | −3.4; 1.0 | 0.28 |
| FRS | −0.7 | −2.1; 0.6 | 0.28 |
| HTN | 0.1 | −20.9; 21.3 | 0.98 |
| CC-IMT | −25.0 | −75.9; 25.9 | 0.32 |
| TPA | −9.5 | −30.1; 11.2 | 0.36 |
| Plaque density | −0.01 | −0.03; 0.01 | 0.28 |
| Plaque composition | −26.9 | −46.4; −74 | 0.007 |
| WM volume | |||
| Variable | β | CI (95%) | p |
| (Intercept) | 755.6 | 627.1; 884.0 | <0.0001 |
| Age | −1.7 | −2.9; −0.5 | 0.008 |
| eGFR | 0.3 | −0.04; 0.7 | 0.08 |
| N° segments | −6.1 | −11.6; −0.7 | 0.03 |